. home.aspx



MJ Hudson advises 4BIO Capital on the establishment of a closed-ended venture fund

September 09, 2019 / Private Equity Wire

MJ Hudson has advised 4BIO Partners LLP (4BIO) on the establishment of a closed-ended venture capital fund. 4BIO is a London-based investment firm that invests in venture capital and public equities in life sciences focusing on gene, cell and RNA-based therapies. The fund focuses on investments in unlisted life sciences companies with a focus on development stage clinical life sciences, pre-clinical life sciences, early clinical life sciences, and advanced therapeutics. 4BIO is seeking to raise up to USD150 million of investor commitments. MJ Hudson law division supported the 4BIO team right from the outset of the launch of their new fund proposition, providing legal and structural advice, as well as managing other service providers to first closing. In addition to the current mandate, MJ Hudson has provided advice and strategic support relating to the sub-advisory roles undertaken by the 4BIO team for other managers as well as potential launch of a listed life sciences fund.